Document Detail


Increased esophageal mucosal/submucosal blood flow in patients with gastroesophageal reflux disease: normalization by treatment with a proton pump inhibitor.
MedLine Citation:
PMID:  17725600     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND AIM: Mucosal injury caused by gastroesophageal reflux may result in changes in esophageal mucosal blood flow. Little is known about esophageal mucosal blood flow in patients with gastroesophageal reflux disease (GERD). Here we examined esophageal mucosal blood flow and the effects of treatment in patients with GERD. METHODS: The subjects included 41 cases (21 males and 20 females, mean age 64.2 years) in whom endoscopy was warranted in patients complaining of heartburn and/or regurgitation. We also studied six normal control subjects. Patients underwent endoscopy, laser Doppler flow meter measurements, and endoscopic ultrasonography before and after treatment. RESULTS: Esophageal mucosal/submucosal blood flow was increased in patients with GERD compared with the control patients. The thickness of the whole esophageal wall and that of the mucosal and submucosal layers of the esophagus correlated significantly with esophageal mucosal/submucosal blood flow. The increased esophageal mucosal/submucosal blood flow significantly decreased after 4 weeks' treatment with lansoprazole, a proton pump inhibitor. CONCLUSION: Our results indicated that the pathophysiology or underlying mechanisms of GERD includes increased esophageal mucosal/submucosal blood flow, which correlates with the thickness of the esophageal wall, but is reversible and responds to treatment with lansoprazole. This suggests that proton pump inhibitors can effectively treat GERD and promote histological normalization of the mucosa and submucosa in the lower esophagus.
Authors:
Shinichiro Mine; Takeshi Iida; Takahiro Tabata; Yosuke Okada; Yoshiya Tanaka
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-08-27
Journal Detail:
Title:  Journal of gastroenterology and hepatology     Volume:  23     ISSN:  1440-1746     ISO Abbreviation:  J. Gastroenterol. Hepatol.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-21     Completed Date:  2008-04-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8607909     Medline TA:  J Gastroenterol Hepatol     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  303-9     Citation Subset:  IM    
Affiliation:
The Department of Internal Medicine, Hagiwara Central Hospital, Kitakyushu, Fukuoka, Japan. s-mine@med.uoeh-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use*
Adult
Aged
Aged, 80 and over
Endoscopy, Gastrointestinal
Esophagus / blood supply*,  drug effects,  pathology
Famotidine / therapeutic use
Female
Gastroesophageal Reflux / diagnosis,  drug therapy*,  physiopathology*
Histamine H2 Antagonists / therapeutic use
Humans
Laser-Doppler Flowmetry
Male
Middle Aged
Mucous Membrane / blood supply*,  drug effects,  pathology
Proton Pump Inhibitors / therapeutic use*
Questionnaires
Regional Blood Flow / drug effects
Ultrasonography
Chemical
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Histamine H2 Antagonists; 0/Proton Pump Inhibitors; 103577-45-3/lansoprazole; 76824-35-6/Famotidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation ther...
Next Document:  Functional hepatic recovery after xenotransplantation of cryopreserved fetal liver cells or soluble ...